Search research articles
Contact Us
Filters
Showing results (111-120 of 136) with videos related to
Page
of 14
Sort By:
Plos One
|
July 5, 2012
Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate
Karen Nieto, Margit Weghofer, Peter Sehr, et al.
Journal of Virology
|
May 19, 2017
Spontaneous and Vaccine-Induced Clearance of Mus Musculus Papillomavirus 1 Infection
Rosie T Jiang, Joshua W Wang, Shiwen Peng, et al.
Cancer Research
|
February 19, 2013
Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity
Tae Heung Kang, Chih-Ping Mao, Sung Yong Lee, et al.
Journal of Medicinal Chemistry
|
December 29, 2010
α,β-Unsaturated carbonyl system of chalcone-based derivatives is responsible for broad inhibition of proteasomal activity and preferential killing of human papilloma virus (HPV) positive cervical cancer cells
Martina Bazzaro, Ravi K Anchoori, Mohana Krishna R Mudiam, et al.
Plos One
|
January 16, 2020
Structure-function analyses of candidate small molecule RPN13 inhibitors with antitumor properties
Ravi K Anchoori, Marietta Tan, Ssu-Hsueh Tseng, et al.
Vaccines
|
June 27, 2024
Vaccination with a Human Papillomavirus L2 Multimer Provides Broad Protection against 17 Human Papillomavirus Types in the Mouse Cervicovaginal Challenge Model
Zhenwei Han, Shen Wang, Ting Mu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 5, 2013
Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors
Chao-Yi Wu, Li-Hua Yang, Huang-Yu Yang, et al.
JCO Global Oncology
|
February 13, 2025
Optimizing Recruitment and Retention in Cancer Clinical Trials in Low-Resource Settings: Barriers and Facilitators From Nigerian Provider's Perspectives
Babayemi O Olakunde, Ngozi Idemili-Aronu, Tara M Friebel-Klingner, et al.
JCO Global Oncology
|
October 8, 2025
Barriers and Facilitators to Cancer Clinical Trial Participation: Perspectives of Patients in the ICON-3 Practice-Based Research Network, Nigeria
Ngozi Idemili-Aronu, Babayemi O Olakunde, Tara M Friebel-Klingner, et al.
ACS Omega
|
October 6, 2018
Covalent Rpn13-Binding Inhibitors for the Treatment of Ovarian Cancer
Ravi K Anchoori, Rosie Jiang, Shiwen Peng, et al.
Page
of 14
Search research articles
Search
Showing results (111-120 of 136) with videos related to
Sort By:
Page
of 14
Plos One
|
July 5, 2012
Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate
Karen Nieto, Margit Weghofer, Peter Sehr, et al.
Journal of Virology
|
May 19, 2017
Spontaneous and Vaccine-Induced Clearance of Mus Musculus Papillomavirus 1 Infection
Rosie T Jiang, Joshua W Wang, Shiwen Peng, et al.
Cancer Research
|
February 19, 2013
Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity
Tae Heung Kang, Chih-Ping Mao, Sung Yong Lee, et al.
Journal of Medicinal Chemistry
|
December 29, 2010
α,β-Unsaturated carbonyl system of chalcone-based derivatives is responsible for broad inhibition of proteasomal activity and preferential killing of human papilloma virus (HPV) positive cervical cancer cells
Martina Bazzaro, Ravi K Anchoori, Mohana Krishna R Mudiam, et al.
Plos One
|
January 16, 2020
Structure-function analyses of candidate small molecule RPN13 inhibitors with antitumor properties
Ravi K Anchoori, Marietta Tan, Ssu-Hsueh Tseng, et al.
Vaccines
|
June 27, 2024
Vaccination with a Human Papillomavirus L2 Multimer Provides Broad Protection against 17 Human Papillomavirus Types in the Mouse Cervicovaginal Challenge Model
Zhenwei Han, Shen Wang, Ting Mu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 5, 2013
Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors
Chao-Yi Wu, Li-Hua Yang, Huang-Yu Yang, et al.
JCO Global Oncology
|
February 13, 2025
Optimizing Recruitment and Retention in Cancer Clinical Trials in Low-Resource Settings: Barriers and Facilitators From Nigerian Provider's Perspectives
Babayemi O Olakunde, Ngozi Idemili-Aronu, Tara M Friebel-Klingner, et al.
JCO Global Oncology
|
October 8, 2025
Barriers and Facilitators to Cancer Clinical Trial Participation: Perspectives of Patients in the ICON-3 Practice-Based Research Network, Nigeria
Ngozi Idemili-Aronu, Babayemi O Olakunde, Tara M Friebel-Klingner, et al.
ACS Omega
|
October 6, 2018
Covalent Rpn13-Binding Inhibitors for the Treatment of Ovarian Cancer
Ravi K Anchoori, Rosie Jiang, Shiwen Peng, et al.
Page
of 14